You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 941 Botensilimab modulates innate and adaptive gene expression programs resulting in superior immune stimulation relative to a first-generation anti-CTLA-4 antibody

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immune Cell Types and Biology
941 Botensilimab modulates innate and adaptive gene expression programs resulting in superior immune stimulation relative to a first-generation anti-CTLA-4 antibody
Free

Authors

Citation

Krishnan S, Chow J, Soh KT, et al
941 Botensilimab modulates innate and adaptive gene expression programs resulting in superior immune stimulation relative to a first-generation anti-CTLA-4 antibody
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0941

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.